Wird geladen...
Towards better combination regimens of cytarabine and FLT3 inhibitors in acute myeloid leukemia
BACKGROUND: AML patients with FLT3/ITD mutations have poor response to cytarabine-based chemotherapy. FLT3 inhibitors (FLT3i) may resensitize cells to cytarabine (CYT). Improving treatment outcome of this combination may benefit from a mechanistic extrapolation approach from in vitro data. METHODS:...
Gespeichert in:
| Veröffentlicht in: | Cancer Chemother Pharmacol |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7539618/ https://ncbi.nlm.nih.gov/pubmed/32748108 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04114-z |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|